IAM
REGN icon

Impact Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Impact Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$4.29M Buy
6,760
+240
+4% +$165K 1.68% 30
2024
Q4 		$4.64M Hold
6,520
– – 1.84% 26
2024
Q3 		$6.85M Buy
+6,520
New +$7.26M 2.64% 12

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Impact Asset Management's REGN Position: Q1 2025 in Review

Impact Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 3.7% in Q1 2025, buying an estimated $165K and bringing the position to 6,760 shares worth $4.29M. The position accounts for 1.68% of the portfolio, ranked #30.

Impact Asset Management first reported a position in REGN in Q3 2024 and has held it in 3 quarters since. The position peaked at $6.85M in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Impact Asset Management held 6,760 shares of Regeneron Pharmaceuticals worth $4.29M as of Q1 2025.
  • Impact Asset Management bought 240 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $165K.
  • Regeneron Pharmaceuticals made up 1.68% of Impact Asset Management's portfolio in Q1 2025, its #30 holding.
  • Impact Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Impact Asset Management's Regeneron Pharmaceuticals position peaked at $6.85M in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Impact Asset Management's 13F filing for Q1 2025, filed 14 Aug 2025.